ArticlePharmacoEconomics2026
A Method for Comparing Health Inequality Impact Magnitudes, with an Illustration for Hypothetical Treatments of 1336 Diseases.
Article in PharmacoEconomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe aimed to facilitate the comparison and communication of magnitudes of health inequality impact across interventions for different diseases, and to indicate the potential range of such impacts.
methodsWe propose rescaling the slope index of inequality to measure the health inequality impact as the change in the gap in total predicted quality-adjusted life-years between the least and most socially disadvantaged groups, with linear regression predictions used to account for effects on intermediate groups. We suggest reporting the inequality impact relative to the total health opportunity cost to facilitate comparison across interventions varying in scale and unit costs. We illustrated the approach with aggregate distributional cost-effectiveness analyses of hypothetical treatments for 1336 diseases in England. We approximated benefit shares for neighbourhood deprivation quintile groups using disease-specific hospital admissions. We tested between-group equality using generalised linear regression and constructed uncertainty intervals using Monte Carlo simulation. We assumed an equal total health opportunity cost and benefit-cost ratio of one, with alternative scenarios in a sensitivity analysis.
resultsHealth inequality impacts of hypothetical treatments ranged from - 33.1% of the total health opportunity cost (inequality increasing) to + 45.3% (inequality decreasing), and were ≤ - 5% for 1.6% of diseases, ≥ + 5% for 41.8% and ≥ + 20% for 1.6%. The impact was positively associated with the benefit-cost ratio and decreased when more deprived groups were assumed to incur proportionately more total health opportunity costs.
conclusionsHealth inequality impacts can be compared using the change in the total predicted quality-adjusted life-year gap between the least and most socially disadvantaged groups as a proportion of the total health opportunity cost.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.